|
Thank you all. Your wishes and prayers mean a lot.
This is an interesting phase 2 trial as it is a single drug that attaches to her2 as well as the immune system. The phase one included 17 patients where 1 achieved complete remission, 2 achieved partial remission and 2 maintained stable disease. I wasn't crazy about these odds but according to Caryn's Onc they're outstanding for a phase one trial. 60 people will particpate in 15-20 centers in the US.
The schedule is also interesting...
* Week one: screening
* Week two: 1st infusion (3 hr infusion and 6 hours observation)
* Week three: 2nd infusion (3 hr infusion and 6 hours observation)
* Week four: 3rd infusion (3 hr infusion and 6 hours observation)
* Week five: follow up
* One month later: follow up
* One month later: follow up
* Two months later: follow up
* Two months later: follow up and if response is seen return in one month to confirm response.
I'll keep everyone informed.
Eric
|